Volume 30, Issue 168, February 2026

The role of innovative studies DUO-E treatment in recurrent endometrial cancer - case report

Natalia Gierulska^1♦, Katarzyna Lachowska¹, Joanna Ocicka¹, Julia Orzelska¹, Patrycja Wójcikiewicz¹, Amelia Trzcińska¹, Aleksandra Kubas², Rafał Tarkowski³, Krzysztof Kułak³

¹Student’s Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, Staszic 16 St., 20-081 Lublin, Poland
²University Clinical Hospital No.2 of Medical University of Lodz, Pomorska 251 St., 92-213 Łódź, Poland
³1st Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszic 16 St., 20-081 Lublin, Poland

^♦Corresponding author
Natalia Gierulska, Student’s Scientific Association at the 1st Chair and Department of Oncological Gynecology and Gynecology, Medical University of Lublin, Staszic 16 St., 20-081 Lublin, Poland

ABSTRACT

Recurrences of endometrial cancer occur in the early stages. Until now, the primary treatment has been platinum-based chemotherapy. However, there is hope in the use of immunotherapy. A 56-year-old patient went to the hospital for a planned ovariohysterectomy. Hystopathological examination performed after surgery revealed tubular endometrial adenocarcinoma G2. After the first stage of radiotherapy a patient had a complete response to treatment. CT-scan showed a remission of lesions after 36 months. After performing the appropriate tests, doctors qualified the patient for the DUO-E study, during which she received six cycles of Durvalumab. The treatment with Durvalumab resulted in a reduction of the tumor. The case highlights the benefits of combining surgery with radiotherapy and immunotherapy. The DUO-E study stands out for its use of a PARP inhibitor. This gives hope for the individualisation of therapy in the future.

Keywords: Recurrence, Endometrial Cancer, Clinical Trial, DUO-E study, Durvalumab

Medical Science, 2026, 30, e38ms3766

PDF

DOI: https://doi.org/10.54905/disssi.v30i168.e38ms3766

Published: 21 February 2026